Capital Advisors, Ltd. LLC Igm Biosciences, Inc. Transaction History
Capital Advisors, Ltd. LLC
- $759 Million
- Q1 2025
A detailed history of Capital Advisors, Ltd. LLC transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Capital Advisors, Ltd. LLC holds 258 shares of IGMS stock, worth $340. This represents 0.0% of its overall portfolio holdings.
Number of Shares
258Holding current value
$340% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IGMS
# of Institutions
83Shares Held
19.4MCall Options Held
61.3KPut Options Held
36.7K-
Baker Bros. Advisors LP New York, NY4.09MShares$5.4 Million0.28% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.57MShares$4.71 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY3.33MShares$4.4 Million0.9% of portfolio
-
Redmile Group, LLC San Francisco, CA2.95MShares$3.9 Million1.41% of portfolio
-
Goldman Sachs Group Inc New York, NY978KShares$1.29 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $38.2M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...